The hormone replacement therapy market in Asia Pacific is expected to register the highest CAGR during the forecast period. In 2023, North America held the largest market share. Growing adoption of the latest technologies, initiatives by profit and nonprofit organizations, and strategies adopted by key players contribute to the upsurging hormone replacement therapy market size in North America. According to the Menopause Foundation of Canada Landmark Report from 2022, over 95% of women experience menopausal symptoms, including mood swings, hot flashes, sexual dysfunction, cognitive changes, and sleep disturbances. These changes can significantly impact a person’s overall health, social relationships, productivity at work, and quality of life.
The Menopause Foundation of Canada (MFC) is a legally recognized nonprofit organization that promotes the assistance that women require during their menopausal years from experts in the government, business community, and healthcare system. Many of Canada’s top menopause experts are on the Medical Advisory Board.
Emerging countries such as India, China, Argentina, Brazil, the UAE, and South Africa are expected to offer significant opportunities for the market players because of their large populations and growing awareness of hormonal imbalances and related conditions. Healthcare professionals have the opportunity to provide HRT services, including hormone testing, prescriptions, monitoring, and consultations. Pharmaceutical companies can meet the increasing demand by providing hormone replacement medications and related products. Success in these markets requires collaborating with local healthcare professionals and comprehending the population’s unique needs.
Hormone Replacement Therapy Market: Segmental Overview
By therapy, the hormone replacement therapy market is segmented into estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, testosterone replacement, and others. The estrogen hormone replacement segment held the largest market share in 2023. The market, by application, is categorized into menopause, growth hormone (GH) deficiency, hypothyroidism, hypogonadism, and others. The menopause segment held the largest hormone replacement therapy market share in 2023 and is anticipated to register the highest CAGR during the forecast period. In terms of route of administration, the market is segmented into oral, parenteral, and others. The oral segment held the largest share of the market in 2023. The market, by end user, is segmented into hospitals, specialty clinics, and others.
The hormone replacement therapy market report, based on geography, is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Hormone Replacement Therapy Market: Competitive Landscape and Key Developments
AstraZeneca; Pfizer Inc.; Novartis AG; Abbott; Tolmar Inc.; Par Pharmaceutical; Mayne Pharma Group Limited; Novo Nordisk A/S; Eli Lily And Company; and Noven Pharmaceuticals, Inc. are among the prominent players profiled in the hormone replacement therapy market report. These companies capitalize on product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the market.
A few of the recent developments in the global market, as per the company press releases, are mentioned below:
• EQT Life Sciences announced that Amolyt Pharma, one of the companies in its portfolio, had agreed to be acquired by Alexion, AstraZeneca Rare Diseases, for a total deal value of US$ 1.05 billion, effective March 2024. Amolyt is a biotechnology company in the clinical stage that specializes in creating innovative therapies for uncommon endocrine disorders. One of the most common rare diseases, hypoparathyroidism, is being treated by Amolyt Pharma. An estimated 115,000 Americans and 107,000 European Union citizens are impacted by it, with women making up about 80% of those affected.
• An exclusive distribution agreement has been reached between Er-Kim, an international pharmaceutical company that specializes in the commercialization of innovative therapies, and Ascendis Pharma A/S, a Danish company, for the latter’s endocrinology portfolio in January 2024. Regarding Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, Malta, Montenegro, North Macedonia, Slovakia, Slovenia, Poland, Romania, Serbia, and Turkey, the agreement names Er-Kim as the exclusive distributor of Ascendis A/S endocrinology.
• In June 2023, Pfizer Inc. and OPKO Health Inc. announced that NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, has been approved by the US Food and Drug Administration (FDA) for treating pediatric patients aged three years and above who have growth failure due to insufficient endogenous growth hormone secretion.